Skip to main content
Armata Pharmaceuticals, Inc. logo

Armata Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · ARMP ISIN · US04216R1023 LEI · 549300QM1VCWH8KT0S21 US Manufacturing
Open in API
Filings indexed 1,011 across all filing types
Latest filing 2016-06-06 Major Shareholding Noti…
Country US United States of America
Listing US ARMP

About Armata Pharmaceuticals, Inc.

https://www.armatapharma.com/

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to developing pathogen-specific bacteriophage therapeutics to combat the global threat of antibiotic-resistant infections. The company's core focus is on creating precisely targeted, high-purity phage-based treatments for serious bacterial infections. This approach aims to provide an effective alternative to conventional antibiotics by eliminating harmful bacteria while preserving the patient's healthy microbiome. Armata's pipeline includes product candidates targeting multi-drug resistant pathogens, supported by its in-house cGMP manufacturing facility for clinical and commercial supply.

Recent filings

Filing Released Lang Actions
EMPERY ASSET MANAGEMENT, LP
Major Shareholding Notification
2016-06-06 English
SABBY 13G APHB 6.02.16
Major Shareholding Notification
2016-06-02 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to an offering of common stock and warrants. It includes detailed terms of the securities offering, pricing, use of proceeds, risk factors, and other information typical of a securities offering document. The presence of terms like 'prospectus supplement', 'offering', 'shares of common stock', 'warrants', and references to the Securities and Exchange Commission (SEC) filings indicate this is a capital raising document. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. The document is not an annual or quarterly report, audit report, earnings release, or any other category. Therefore, the correct classification is CAP.
2016-06-01 English
8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated June 1, 2016, reporting a material definitive agreement related to a securities purchase agreement and unregistered sales of equity securities. It details the terms of a financing transaction including share issuance, warrants, placement agency agreement, and related disclosures. The content focuses on capital raising activities and financing terms rather than financial results, management changes, or other report types. The document is not an earnings release, annual or interim report, or proxy statement. It is a current report on material events affecting the company’s capital structure. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail support a high confidence in this classification.
2016-06-01 English
DEF 14A
Proxy Solicitation & Information Statement
2016-05-20 English
Regulatory Filings 2016
Regulatory Filings
2016-05-16 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.